SRF231, a fully human high-affinity anti-CD47 antibody, exerts potent preclinical antitumor activity through engagement of the Fc receptor (FcR), CD32a
JOURNAL FOR IMMUNOTHERAPY OF CANCER(2019)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
JOURNAL FOR IMMUNOTHERAPY OF CANCER(2019)